Patient-Preferences Favoring Treatment Discontinuation Are Reduced with Vedolizumab and Ustekinumab Compared with TNF Antagonists in Inflammatory Bowel Disease
Anand Kumar, Emilie S. Kim, Philip Kozan, Vinita Jacob, Randy S. Longman, Ellen J. Scherl, Robert J. Battat, Dana J. Lukin
Research output: Contribution to journal › Article › peer-review
4Scopus
citations
Fingerprint
Dive into the research topics of 'Patient-Preferences Favoring Treatment Discontinuation Are Reduced with Vedolizumab and Ustekinumab Compared with TNF Antagonists in Inflammatory Bowel Disease'. Together they form a unique fingerprint.